An ink is provided, which includes a resin, UV curable monomer, and photo initiator. The resin is formed by reacting a plurality of end capping agents with a dendrimer compound in an environment including esterification catalyst, inhibitor, and first solvent. The dendrimer compound is formed by reacting a multi-hydroxy compound and a plurality of hydroxy-containing epoxy compounds in an environment including alkaline catalyst and second solvent. The multi-hydroxy compound and the hydroxy-containing epoxy compounds have a molar ratio of 1:6 to 1:20, and the multi-hydroxy compound and the end capping agents have a molar ratio of 1:6 to 1:20. The end capping agents include acrylic acid, methacrylic acid, glycidyl methacrylate, or 2-amino acrylic acid. The resin and the UV curable monomer have a weight ratio of 100:30 to 100:5000, and the resin and the photo initiator have a weight ratio of 100:30 to 100:500.

The present invention relates to an antibacterial co-polymer comprising a water soluble backbone polymer having in at least one end a dendritic or hyperbranched polymer of generation 1 to 6 wherein at least one functional group comprising a carboxylic amine has been covalently attached to the periphery of the dendritic or hyperbranched polymer. The present invention also relates to said anti-bacterial co-polymer when said co-polymer has been cross-linked with a cross-linking agent and to uses of the cross-linked co-polymer in a hydrogel for the treatment or prevention of bacterial infections, particularly in surgical site infections (SSIs).

The present invention relates to a hyperbranched polyether of formula (I) R.sub.mQ.sub.n-0-R.sup.1 (I), wherein Q is a branching unit of formula, n is 2.sup.k1, m is 2.sup.k, k is 2, 3, 4, 5 or 6, each R is independently a hydrocarbon radical having at least 10 carbon atoms, R.sup.1 is a polymer having a number average molecular weight M.sub.n of at least 250 g/mol, wherein each branching unit Q is connected via ether linkage to adjacent branching units Q and each terminal oxygen of Q, not connected to adjacent branching units Q, is connected to R via ether linkage, as well as mixtures thereof. The present invention further relates to formulations comprising said hyperbranched polyether or mixture of ethers as well as their use.

##STR00001##

This invention is directed to a biodegradable polymer that can be degraded in vivo. The biodegradable polymer comprises a biodegradable polymer segment having at least a biodegradable bond and two or more cationic components, wherein each of said cationic components is covalently attached to the biodegradable polymer segment and the two cationic components/molecules are separated by at least one biodegradable bond in the backbone. The biodegradable polymer can be used for targeting desired ceils in vivo including T cells, NK (natural killer) ceils, cancer cells, or a combination thereof, delivering genes, DNA, oligodeoxynucleotide, oligonucleotide, RNA, mRNA, RNAi, siRNA, microRNA, protein, peptide, antibody, fragment of an antibody, small molecule drug including chemotherapy drugs, or other bioactive agents into cells, or being used as a vaccine or drug for treating a disease such as a cancer in a subject.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

A multiple-metal salt assembly of a dendrimer in which multiple-metal salt compounds with a number of, for example, four or more types of multiple metals can be assembled for each of parts with different environments so that the total metal atom number becomes less than 60. Also, a method for producing the multiple-metal salt assembly, and a method for producing subnano metal particles including the multiple-metal salt assembly of the dendrimer.

According to the present disclosure, a bioadhesive formulation is provided. The bioadhesive formulation comprises a polycaprolactone dendrimer having a dendrimer core and a plurality of polycaprolactone chains extending from the dendrimer core, wherein at least one of the polycaprolactone chains has an end which is covalently attached with a diazirine, and wherein the diazirine converts to a carbene or a diazoalkyl when a stimulant is applied to the bioadhesive formulation. Methods of forming the bioadhesive formulation are also provided. The bioadhesive could be used in (i) the prevention of thrombosis from tissue fixation and/or (ii) the relief of discomfort and/or pain during and/or after surgery. Preferably, the bioadhesive formulation further comprises a hygroscopic additive, an antithrombotic agent, and/or an anaesthetic agent.

An ink is provided, which includes a resin, UV curable monomer, and photo initiator. The resin is formed by reacting a plurality of end capping agents with a dendrimer compound in an environment including esterification catalyst, inhibitor, and first solvent. The dendrimer compound is formed by reacting a multi-hydroxy compound and a plurality of hydroxy-containing epoxy compounds in an environment including alkaline catalyst and second solvent. The multi-hydroxy compound and the hydroxy-containing epoxy compounds have a molar ratio of 1:6 to 1:20, and the multi-hydroxy compound and the end capping agents have a molar ratio of 1:6 to 1:20. The end capping agents include acrylic acid, methacrylic acid, glycidyl methacrylate, or 2-amino acrylic acid. The resin and the UV curable monomer have a weight ratio of 100:30 to 100:5000, and the resin and the photo initiator have a weight ratio of 100:30 to 100:500.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

Disclosed are the cation polymers capable of removing their positive charges in oxidative conditions, preparation methods, and applications as gene delivery carriers. The oxidation-responsive unit is the p-(boronic acid or ester)benzylammonium, which upon oxidation eliminates p-hydroxymethlphenol and thus converts in a tertiary amine. Compared with the prior art, different from a common quaternary amination carrier, the synthesized charge reversal type gene delivery carrier for oxidative response of the present invention has a large quantity of positive charges and can well coat a DNA, but the positive charges can be removed under the condition of intracellular oxidation when the charge reversal type gene delivery carrier enters a cell, a charge reverse is triggered, the positive charges turn to negative charges, and the DNA is quickly released for transfection. The carrier is efficient, low in toxicity, and good in application prospect.